Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study
Abstract Background Oral methotrexate (MTX) is the first-line therapy for patients with rheumatoid arthritis (RA).However, approximately one quarter of patients discontinue MTX within 12 months.MTX failure, defined as MTX cessation or the addition of another anti-rheumatic drug, is usually due adverse event(s) and/or inefficacy.The aims of this stu